CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 101 enrolled
Drug / intervention
esomeprazole 40 mgdrug
Likely dose
esomeprazole 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01249651
NCT01249651Phase 4Completed
CompareCT.gov

An 8-week, Open Label, Multicentre Study to Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects With Continuing Symptoms of Heartburn Following Treatment With a Previous Rabeprazole.

AstraZeneca·interventional·Posted Nov 30, 2010·Updated Oct 31, 2012

In Brief

A Phase 4 clinical trial evaluating esomeprazole 40 mg for Heartburn. Completed, enrolled 101 participants across 1 site.

Detailed Summary

Administration of esomeprazole 40 mg to subjects who still had heartburn after receiving rabeprazole 20 mg once daily for 4 to 8 weeks will result in statistically significant improvement of heartburn after 8-week treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeartburn
CountriesChina
CollaboratorsQuintiles, Inc.

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedNov 30, 2010
Enrollment StartNov 1, 2010
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.6 years ago

Interventions

esomeprazole 40 mgdrug

esomeprazole 40 mg once daily, 8 weeks